These strategies based on CTC detection are complementary to those involving the determination of prostate cancer biomarkers such as prostate-specific antigen (PSA) [20,21,22] and prostate cancer antigen 3 (PCA3) [23,24,25]. This evidence concerns the gene PCA3 and Familial prostate cancer.